Metoprololsuccinat Orion (Metoprolol Succinate)

Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart. By inhibiting sympathetic stimulation, it slows the heart rate, reduces the force of contraction, and lowers cardiac output, which together decrease arterial pressure and myocardial oxygen demand.

The appropriate dose of Metoprololsuccinat Orion is determined by the prescribing clinician based on the patient’s condition, response, and any comorbidities. Dosage may be adjusted over time to achieve target blood‑pressure or heart‑failure goals.

Safety in pregnancy and lactation has not been fully established. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol succinate is a long‑acting, cardio‑selective β1‑blocker, offering once‑daily dosing and a smoother plasma‑level profile compared with short‑acting agents like propranolol. Its selectivity reduces the likelihood of bronchospasm, making it a preferred choice for patients with respiratory concerns.

Store Metoprololsuccinat Orion at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains sealed until use.

Metoprololsuccinat Orion is taken orally, usually as a whole tablet swallowed with water. It is commonly prescribed once daily, but the exact schedule should follow the prescriber’s instructions.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and rare allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Metoprololsuccinat Orion is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.